FDA Evaluates Unapproved Peptide Substances

The Food and Drug Administration (FDA) is examining seven unapproved peptide substances known for their alleged health benefits. This evaluation occurs at the FDA’s White Oak Campus in Silver Spring, Maryland, where the Pharmacy Compounding Advisory Committee will discuss the possibility of including these peptides in the agency’s 503A Bulks List, allowing their use in specific compounded prescription drugs.

Although these peptides lack FDA approval, they are readily available through wellness clinics, compounding operations, and online sellers. HHS Secretary Robert F. Kennedy Jr. has shown support for expanding peptide therapies, while FDA reviewers express concerns about the limited evidence regarding the safety and effectiveness of these substances.

Growing Demand for Peptides

According to Reuters, consumer interest remains strong due to peptides being popular for weight loss, muscle building, performance enhancement, chronic disease management, and wound repair. The FDA documents reveal these peptides under review:

• BPC-157: Proposed for ulcerative colitis, available in oral capsules, nasal spray, injections, transdermal cream, and rectal suppository.
• TB-500: Intended for wound healing, available in subcutaneous or intramuscular injections.
• KPV: Targets wound healing and inflammatory conditions, available in cream and gel form.
• MOTS-c: Proposed for obesity and osteoporosis, available as subcutaneous injection.
• Semax: Aimed at cerebral ischemia, migraines, and trigeminal neuralgia, available in intranasal spray and subcutaneous injection.
• Emideltide: Proposed for opioid withdrawal, chronic insomnia, narcolepsy, available in subcutaneous injection.
• Epitalon: Intended for insomnia, available in subcutaneous injection.

Expert Opinions and Concerns

Dr. Alex Tatem, a performance medicine and peptide expert, will testify at the FDA hearings. He notes the review of various products, stating each targets a distinct issue faced by patients. Tatem highlights the safety of BPC-157 compared to common over-the-counter options like ibuprofen, which the FDA warns may cause serious side effects.

Dr. Marc Siegel, Fox News senior medical analyst, emphasizes the need for careful study of these substances, expressing concerns about kidney impacts and the necessity of rigorous clinical trials.

Future Expectations

Tatem anticipates intense discussions at the hearings and hopes committee members will consider claims of real-world data from millions of doses administered with minimal adverse events. Following the committee’s recommendation, the FDA would still need to complete the review and rulemaking process to formalize the inclusion of any substances on the 503A Bulks List.

There is potential for the FDA to allow temporary enforcement for certain substances while rulemaking continues, although no announcement has been made on this matter.

Tatem encourages involvement from individuals by reaching out to local representatives for access to safe, regulated peptides. The FDA and ibuprofen product manufacturer Haleon have been contacted for comments.